Journal
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
Volume 4, Issue 1, Pages 46-52Publisher
WILEY
DOI: 10.1002/acn3.377
Keywords
-
Categories
Funding
- US National Multiple Sclerosis Society [RG4856]
- NIH/NINDS [K02NS072288, R01NS092835, R01NS026799, R01NS049477]
- Gottfried and Julia Bangerter-Rhyner Foundation
- Freiwillige Akademische Gesellschaft (Basel, Switzerland)
Ask authors/readers for more resources
A patient with relapsing multiple sclerosis (RMS) was treated with a standard immunomodulatory therapy, but due to ongoing disease activity was switched to rituximab. Relapses ceased, but secondary progressive MS (SPMS) eventually appeared, associated with new focal spinal cord white matter lesions. Cerebrospinal fluid (CSF) showed persistent oligoclonal bands (OCB) and clonally related B cells in CSF and peripheral blood. The treatment escalation approach failed to prevent evolution to SPMS, raising the question of whether initiation of B-cell depleting therapy at the time of RMS diagnosis should be tested to more effectively address the immune pathology leading to SPMS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available